{
  "report_rows": [
    {
      "kpi": "Q2 adjusted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$1.62 vs. cons $1.59",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 revenue",
      "prediction": "IN-LINE",
      "answer": "pred ~$1.35B vs. cons $1.34B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 EBITDA",
      "prediction": "IN-LINE",
      "answer": "pred ~$722M vs. cons $719M",
      "confidence": "LOW"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 adjusted EPS",
      "prediction": "LOWER",
      "answer": "guide ~$6.02-$6.12 (midpoint $6.07) vs. cons $6.09 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 capital investment",
      "prediction": "UNCHANGED",
      "answer": "guide ~$3.70B vs. cons $3.70B (FY2026)",
      "confidence": "HIGH"
    },
    {
      "kpi": "Long-term adjusted EPS growth",
      "prediction": "UNCHANGED",
      "answer": "guide ~8.0% midpoint vs. cons 8.0% (2026-2030)",
      "confidence": "HIGH"
    }
  ],
  "day1_residual_pct": -1.8,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -2.8,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "A modest Q2 beat is likely outweighed by FY2026 guidance midpoint ~$6.07 vs. consensus $6.09 and approximately $74.9M of authorized Pennsylvania revenue vs. the updated ~$159.6M request; the out-period math should produce incremental FY2026-FY2027 estimate cuts as analysts incorporate lower Pennsylvania revenue and continued New Jersey timing risk.",
  "day5_confidence": "MEDIUM"
}